학술논문
Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial
Document Type
Article
Author
Adams, Mark; Arya, Mark; Athan, Eugene; Berger, Ira; Bradley, Paul; Briskin, Toby; Glover II, Richard; Griffin, Paul; Kim, Joshua; Kitchener, Scott; Klein, Terry; Leah, Amber; Leelasena, Indika; Lemech, Charlotte; Lickliter, Jason; Manning, Mary Beth; Napier-Flood, Fiona; Nugent, Paul; Thackwray, Susan; Turner, Mark; Mallory, Raburn M ; Formica, Neil; Pfeiffer, Susan; Wilkinson, Bethanie; Marcheschi, Alex; Albert, Gary; McFall, Heather; Robinson, Michelle; Plested, Joyce S; Zhu, Mingzhu; Cloney-Clark, Shane; Zhou, Bin; Chau, Gordon; Robertson, Andreana; Maciejewski, Sonia; Hammond, Holly L; Baracco, Lauren; Logue, James; Frieman, Matthew B; Smith, Gale; Patel, Nita; Glenn, Gregory M
Source
In The Lancet Infectious Diseases November 2022 22(11):1565-1576
Subject
Language
ISSN
1473-3099